A Phase I, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD9164 Given Once Daily as Inhaled Formulation Via Turbuhaler for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A Phase I, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD9164 Given Once Daily as Inhaled Formulation Via Turbuhaler for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2010

At a glance

  • Drugs AZD 9164 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Nov 2010 Planned End Date changed from 1 Jul 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
    • 28 Jun 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 19 May 2010 Official Title amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top